Lucie Z.
- Country
- Czechia
- Department
- Onkologicka klinika 1 LF UK a FTN
Research Overview
- Phase 3 Randomized, Double-Blind Study of Bemarituzumab with mFOLFOX6 in FGFR2b-Overexpressing Advanced Gastric or Gastroesophageal Junction Cancer
- Phase 1b/3 Evaluation of Bemarituzumab, Chemotherapy, and Nivolumab in FGFR2b-Overexpressing Advanced Gastric and Gastroesophageal Junction Cancer
- Evaluation of Safety and Efficacy of Telisotuzumab Adizutecan Combinations in Metastatic Colorectal Cancer: A Phase 2 Open-Label Randomized Study
Data & Insights
Has run more than one trial at 44 of 199 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in advanced treatments for gastric cancer and gastroesophageal junction cancer, with particular emphasis on cases involving specific molecular markers.
- Advanced Gastric Cancer Management
- Gastroesophageal Junction Tumors
- First-line Treatment Approaches
Their research focuses on innovative therapeutic strategies for previously untreated advanced cases.
Molecular Targeted Therapy
The investigator demonstrates expertise in FGFR2b-targeted treatments and their implementation in gastrointestinal cancer care.
- FGFR2b Expression Analysis
- Targeted Therapeutic Approaches
- Biomarker-driven Treatment
Their work involves evaluating novel targeted therapies in combination with established treatment protocols.
Combined Modality Treatment
The investigator explores combination therapy approaches in gastrointestinal oncology, integrating targeted agents with conventional chemotherapy.
- Chemotherapy Combinations
- Treatment Optimization
- Survival Outcome Assessment
Their research encompasses evaluation of treatment efficacy through overall survival metrics.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.